

DAFTAR PUSTAKA

1. UNAIDS 2019 estimates.
2. Kementerian Kesehatan RI. Pusat Data dan Informasi Kementerian Kesehatan RI: HIV-AIDS. 2019.
3. Dinas Kesehatan Daerah Istimewa Yogyakarta. Profil Kesehatan Provinsi DI Yogyakarta Tahun 2017. 2018.
4. Perwitasari D, Arguni E, Dewi Satria C, Hapsari M. Faktor Prediktor Kematian Anak dengan Infeksi HIV yang Mendapat Terapi Antiretrovirus di RSUP Dr. Sardjito Yogyakarta dan RSUP Dr. Kariadi Semarang. *Sari Pediatr*. 2016;18(3):204–8.
5. Cairncross LL, Davidson A, Millar AJW, Pillay K. Kaposi sarcoma in children with HIV: a clinical series from Red Cross Children's Hospital. *J Pediatr Surg*. 2009 Feb;44(2):373–6.
6. Orem J, Otieno MW, Remick SC. AIDS-associated cancer in developing nations. *Curr Opin Oncol*. 2004;16:468–76.
7. Jackson CC, Dickson MA, Sadjadi M, Gessain A, Abel L, Jouanguy E, et al. Kaposi Sarcoma of Childhood: Inborn or Acquired Immunodeficiency to Oncogenic HHV-8. *Pediatr Blood Cancer*. 2016 Mar 1;63(3):392–7.
8. Macken M, Dale H, Moyo D, Chakmata E, Depan S, Israels T, et al. Triple therapy of vincristine, bleomycin and etoposide for children with Kaposi sarcoma: Results of a study in Malawian children. *Pediatr Blood Cancer*. 2017 Feb 1;65.
9. El-Mallawany NK, McAtee CL, Campbell LR, Kazembe PN. Pediatric Kaposi sarcoma in context of the HIV epidemic in sub-Saharan Africa: current perspectives. *Pediatric Health Med Ther*. 2018 Apr;9:35–46.
10. Owiredu W, Quaye L, Amidu N, Addai-Mensah O. Prevalence of anaemia and immunological markers among Ghanaian HAART-naïve HIV-patients and those on HAART. *Afr Health Sci*. 2011;11(1):2–15.
11. Ebiessa G, Deyessa N, Biadgilign S. Predictors of early mortality in a cohort of HIV-infected children receiving high active antiretroviral treatment in public hospitals in Ethiopia. *AIDS Care*. 2015 Jun 3;27(6):723–30.
12. Shet A, Mehta S, Rajagopalan N, Dinakar C, Ramesh E, Samuel NM, et al. Anemia and growth failure among HIV-infected children in India: A retrospective analysis. *BMC Pediatrics*. 2009 Jun 16;9.
13. Burchett SK, Pizzo PA. HIV Infection in Infants, Children, and Adolescents. *Pediatr Rev*. 2003;24.
14. Sazawal S, Black RE, Ramsan M, Chwaya H, Stoltzfus R, Dutta A, et al. Effects of routine prophylactic supplementation with iron and folic acid on

admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. *Lancet*. 2006;367(9505):133–43.

15. Renner LA, Dicko F, Kouéta F, Malateste K, Gueye RD, Aka E, et al. Anaemia and zidovudine-containing antiretroviral therapy in paediatric antiretroviral programmes in the IeDEA Paediatric West African Database to evaluate AIDS. *J Int AIDS Soc*. 2013 Sep 17;16.
16. Bunupuradah T, Kariminia A, Chan KC, Ramautarsing R, Huy BV, Han N, et al. Incidence and predictors of severe anemia in Asian HIV-infected children using first-line antiretroviral therapy. *Int J Infect Dis*. 2013 Oct;17(10):e806–10.
17. Lewis DK, Whitty CJM, Epino H, Letsky EA, Mukiibi JM, van den Broek NR. Interpreting tests for iron deficiency among adults in a high HIV prevalence African setting: routine tests may lead to misdiagnosis. *Trans R Soc Trop Med Hyg*. 2007 Jun;101(6):613–7.
18. Gillespie SL. Pediatric HIV infection: Classification, clinical manifestations, and outcome. UpToDate. 2019;
19. Kementerian Kesehatan RI. Pedoman Penerapan Terapi HIV pada Anak. In 2014.
20. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. World Health Organization; 2007.
21. Newell M, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. *Lancet*. 2004;364:1236–43.
22. The European Collaborative Study. Fluctuations in Symptoms in Human Immunodeficiency Virus-Infected Children: The First 10 Years of Life. *Pediatrics*. 2001;108(1).
23. Guillen S, García San Miguel L, Resino S, Bellón JM, González I, Jiménez de Ory S, et al. Opportunistic infections and organ-specific diseases in HIV-1-infected children: A cohort study (1990-2006). *HIV Medicine*. 2010;11(4):245–52.
24. Gona P, van Dyke RB, Williams PL, Dankner WM, Chernoff MC, Nachman SA, et al. Incidence of Opportunistic and Other Infections in HIV-Infected Children in the HAART Era. *JAMA*. 2006;296(3).
25. Sauvageot D, Schaefer M, Olson D, Pujades-Rodriguez M, O'Brien DP. Antiretroviral therapy outcomes in resource-limited settings for HIV-infected children <5 years of age. *Pediatrics*. 2010 May;125(5).

26. Fenner L, Brinkhof MWG, Keiser O, Weigel R, Cornell M, Moultrie H, et al. Early Mortality and Loss to Follow-up in HIV-Infected Children Starting Antiretroviral Therapy in Southern Africa for the International epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA) [Internet]. Vol. 54, J Acquir Immune Defic Syndr. 2010. Available from: www.iedea-sa.org
27. Walker A, Prendergast AJ, Mugenyi P, Munderi MBChB P, Hakim J, Kekitiinwa A, et al. Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-infected Adults and Children in Uganda and Zimbabwe. *Clin Infect Dis*. 2012;55(12):1707–18.
28. Davies MA, May M, Bolton-Moore C, Chimbetete C, Eley B, Garone D, et al. Prognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: A collaborative analysis of treatment programs. *Pediatr Infect Dis J*. 2014;33(6):608–16.
29. Violari A, Paed FC, Cotton MF, Med M, Gibb DM, Babiker AG, et al. Early Antiretroviral Therapy and Mortality among HIV-Infected Infants. *N Engl J Med*. 2008;359:2233–44.
30. Koller M, Patel K, Chi BH, Wools-Kaloustian K, Dicko F, Chokephaibulkit K, et al. Immunodeficiency in Children Starting Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. *J Acquir Immune Defic Syndr*. 2015;68(1).
31. Mbori-Ngacha D, Nduati R, John G, Reilly M, Richardson B, Mwatha A, et al. Morbidity and Mortality in Breastfed and Formula-Fed Infants of HIV-1-Infected Women: A Randomized Clinical Trial. *JAMA*. 2001;286(19):2413–20.
32. Mphatswe W, Blanckenberg N, Tudor-Williams G, Prendergast A, Thobakgale C, Mkhwanazi N, et al. High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. *AIDS*. 2007;21:1253–61.
33. Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. 2019.
34. Kaposi M. Idiopathisches multiples pigmentsarcom der haut. *Arch Dermatol und Syphilis*. 1872;4:265–73.
35. Duprez R, Lacoste V, Brière J, Couppié P, Frances C, Sainte-Marie D, et al. Evidence for a multiclonal origin of multicentric advanced lesions of kaposi sarcoma. *J Natl Cancer Inst*. 2007 Jul 18;99(14):1086–94.
36. World Health Organization. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 100F. Lyon, France; 2012.



37. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. *Nat Rev Cancer*. 2010 Oct;10(10):707–19.
38. Dollard SC, Butler LM, Jones AMG, Mermin JH, Chidzonga M, Chipato T, et al. Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: Insights on the origin of the “kaposi's sarcoma belt.” *Int J Cancer*. 2010 Nov 15;127(10):2395–401.
39. Wawer MJ, Eng SM, Serwadda D, Sewankambo NK, Kiwanuka N, Gray RH. Prevalence of Kaposi Sarcoma-Associated Herpesvirus Compared With Selected Sexually Transmitted Diseases in Adolescents and Young Adults in Rural Rakai District, Uganda.
40. Butler LM, Were WA, Balinandi S, Downing R, Dollard S, Neilands TB, et al. Human herpesvirus 8 infection in children and adults in a population-based study in rural Uganda. *Journal of Infectious Diseases*. 2011 Mar 1;203(5):625–34.
41. Anderson L, Li Y, Graubard B, Whitby D, Mbisa G, Tan S, et al. Human herpesvirus 8 seroprevalence among children and adolescents in the United States. *Pediatr Infect Dis J*. 2008;27(7):661–4.
42. Wabinga HR, Parkin DM, Wabwire-Mangen F, Namboozee S. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. *Br J Cancer*. 2000;82(9):1585–92.
43. Rohner E, Valeri F, Maskew M, Prozesky H, Rabie H, Garone D, et al. Incidence rate of Kaposi sarcoma in HIV-infected patients on antiretroviral therapy in Southern Africa: A prospective multicohort study. *J Acquir Immune Defic Syndr*. 2014;67(5):547–54.
44. Amir H, Kaaya EE, Manji KP, Kwesigabo G, Biberfeld P. Kaposi's sarcoma before and during a human immunodeficiency virus epidemic in Tanzanian children. *Pediatr Infect Dis J*. 2001;20(5):518–39.
45. de Bruin GP, Stefan DC. Children with Kaposi sarcoma in two Southern African hospitals: Clinical presentation, management, and outcome. *J Trop Med*. 2013;1–6.
46. Stefan DC. Patterns of distribution of childhood cancer in Africa. *J Trop Med*. 2015 Jun 1;61(3):165–73.
47. Dryden-Peterson S, Medhin H, Kebabonye-Pusoentsi M, Seage GR, Suneja G, Kayembe MKA, et al. Cancer incidence following expansion of HIV treatment in Botswana. *PLoS ONE*. 2015 Aug 12;10(8).
48. Parkin DM, Namboozee S, Wabwire-Mangen F, Wabinga HR. Changing cancer incidence in Kampala, Uganda, 1991-2006. *Int J Cancer*. 2010 Mar 1;126(5):1187–95.



49. El-Mallawany NK, Villiera J, Kamiyango W, Mhango J, Slone JS, Mehta PS, et al. Increasing Numbers of New Kaposi Sarcoma Diagnoses in HIV-Infected Children and Adolescents Despite the Wide Availability of Antiretroviral Therapy in Malawi. *Clin Infect Dis*. 2017 Mar 15;64(6):818–9.
50. Mittermayer-Vassallo K, Banda K, Molyneux EM. Kaposi sarcoma in HIV-seronegative children presenting to the paediatric oncology ward in The Queen Elizabeth Central Hospital, Blantyre, Malawi during 2002–2014. *Tropical Doctor*. 2016 Jul 1;46(3):138–42.
51. Chagaluka G, Stanley C, Banda K, Depani S, Nijram'Madzi J, Katangwe T, et al. Kaposi's sarcoma in children: An open randomised trial of vincristine, oral etoposide and a combination of vincristine and bleomycin. *Eur J Cancer*. 2014;50(8):1472–81.
52. Andreoni M, Sarmati L, Nicastri E, Sawaf G el, Zalabani M el, Uccella I, et al. Primary Human Herpesvirus 8 Infection in Immunocompetent Children. *JAMA*. 2002;287(10).
53. Hladik W, Dollard SC, Mermin J, Fowlkes AL, Downing R, Amin MM, et al. Transmission of Human Herpesvirus 8 by Blood Transfusion. *N Engl J Med*. 2006;355(13).
54. Crabtree KL, Wojcicki JM, Minhas V, Kankasa C, Mitchell C, Wood C. Association of Household Food- and Drink-Sharing Practices with Human Herpesvirus 8 Seroconversion in a Cohort of Zambian Children. *J Infect Dis*. 2017 Nov 1;216(7):842–9.
55. Sahin G, Palanduz A, Aydogan G, Cassar O, Ertem AU, Telhan L, et al. Classic Kaposi sarcoma in 3 unrelated Turkish children born to consanguineous kindreds. *Pediatrics*. 2010 Mar;125(3):e704–8.
56. Cox CM, El-Mallawany NK, Kabue M, Kovarik C, Schutze GE, Kazembe PN, et al. Clinical characteristics and outcomes of HIV-infected children diagnosed with kaposi sarcoma in Malawi and Botswana. *Pediatr Blood Cancer*. 2013 Aug;60(8):1274–80.
57. Herce ME, Kalanga N, Wroe EB, Keck JW, Chingoli F, Tengaenga L, et al. Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi. *J Int AIDS Soc*. 2015 May 29;18(1).
58. El-Mallawany NK, Kamiyango W, Slone JS, Villiera J, Kovarik CL, Cox CM, et al. Clinical factors associated with long-term complete remission versus poor response to chemotherapy in HIV-Infected children and adolescents with kaposi sarcoma receiving bleomycin and vincristine: a retrospective observational study. *PLoS ONE*. 2016 Apr 1;11(4).



59. Arkin LM, Cox CM, Kovarik CL. Kaposi's sarcoma in the pediatric population: The critical need for a tissue diagnosis. *Pediatr Infect Dis J*. 2009;28(5):426–8.
60. Patel RM, Goldblum JR, Hsi ED. Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma. *Modern Pathology*. 2004 Apr;17(4):456–60.
61. Pantanowitz L, Otis CN, Dezube BJ. Immunohistochemistry in Kaposi's sarcoma. *Clin Exp Dermatol*. 2010 Jan;35(1):68–72.
62. Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. *Nature Genetics*. 2004 Jul;36(7):683–5.
63. El-Mallawany N, Kamiyango W, Villiera J, Slone J, Kovarik C, Campbell L. Proposal of a Risk-Stratification Platform to Address Distinct Clinical Features of Pediatric Kaposi Sarcoma in Lilongwe, Malawi. *J Glob Oncol*. 2017;
64. Campbell L, Bacha J, Slone J, El-Mallawany N, Mwita L, Mehta P. Characteristics and outcomes of pediatric Kaposi sarcoma patients in the southern highlands zone of Tanzania. Paper presented at: 10th International Conference on Cancer in Africa (AORTIC); November 20, 2015; Marrakech, Morocco. 2015;
65. Anglemyer A, Agrawal AK, Rutherford GW. Treatment of Kaposi sarcoma in children with HIV-1 infection. *Cochrane Database Syst Rev*. 2014 Jan 27;2014(1).
66. Krown SE. Treatment strategies for Kaposi sarcoma in sub-Saharan Africa: Challenges and opportunities. *Curr Opin Oncol*. 2011 Sep;23(5):463–8.
67. Bhutani M, Polizzotto MN, Uldrick TS, Yarchoan R. Kaposi sarcoma-associated herpesvirus-associated malignancies: Epidemiology, pathogenesis, and advances in treatment. *Semin Oncol*. 2015 Apr 1;42(2):223–46.
68. El-Mallawany NK, Wasswa P, Mtete I, Mutai M, Stanley CC, Mtunda M, et al. Identifying opportunities to bridge disparity gaps in curing childhood cancer in Malawi: Malignancies with excellent curative potential account for the majority of diagnoses. *Pediatr Hematol Oncol*. 2017 Jul 4;34(5):261–74.
69. Niedzielska G, Kotowski M, Niedzielski A, Dybiec E, Wiczorek P. Cervical lymphadenopathy in children-Incidence and diagnostic management. *Int J Pediatr Otorhinolaryngol*. 2007 Jan;71(1):51–6.
70. Gantt S, Kakuru A, Wald A, Walusansa V, Corey L, Casper C, et al. Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. *Pediatr Blood Cancer*. 2010 May;54(5):670–4.



71. Rose A, Hall C, Martinez-Alier N. Aetiology and management of malnutrition in HIV-positive children. *Arch Dis Child*. 2014;99:546–51.
72. Kementerian Kesehatan RI. Pedoman Pelayanan Gizi Bagi ODHA. 2014.
73. Anna Thereza Thome Leao AKB. Evaluation of quality of life in HIV-infected children and children with cancer. *Dentistry*. 2015;5:1–7.
74. Pozniak A. Quality of life in chronic HIV infection. *Lancet HIV*. 2014;1:e6–7.
75. Mchenry M, Nyandiko W, Scanlon M, Fischer L, Mcateer C, Aluoch J. HIV Stigma : Perspectives from Kenyan child caregivers and adolescents living with HIV. *J Int Assoc Provid AIDS Care*. 2017;16:215–25.
76. Barennes H, Tat S, Reinharz D, Vibol U. Perceived stigma by children on antiretroviral treatment in Cambodia. *BMC Pediatr*. 2014;14:1–9.
77. Kabue M, Buck W, Wanless S, Cox C, McCollum E, Caviness A. Mortality and clinical outcomes in HIV-infected children on antiretroviral therapy in Malawi, Lesotho, and Swaziland. *Pediatrics*. 2012;18:1–6.
78. Arage G, Assefa M, Worku T, Semahegn A. Survival rate of HIV-infected children after initiation of the antiretroviral therapy and its predictors in Ethiopia: A facility-based retrospective cohort. *SAGE Open Medicine*. 2019 Jan;7:1–8.
79. Sumantri R, Supandiman I, Indjradinata P, van der Ven A, van Crevel R. Peluang kematian penderita Human Immunodeficiency Virus-Acquired Immune Deficiency Syndrome berdasarkan gabungan derajat anemia, indeks massa tubuh, dan jumlah cluster differentiation 4. *Maj Kedokt Bandung*. 2012;44:50–6.
80. Perwitasari D, Arguni E, Satria C, Hapsari M. Faktor prediktor kematian anak dengan infeksi HIV yang mendapat terapi antiretrovirus di RSUP Dr. Sardjito Yogyakarta dan RSUP Dr. Kariadi Semarang. *Sari Pediatr*. 2017;18:1–6.
81. Pham H, Ishizaki A, Nguyen L, Phan C, Phung T, Takemoto K. Two-year outcome of first-line antiretroviral therapy among HIV-1 vertically-infected children in Hanoi, Vietnam. *Int J STD AIDS*. 2015;26:821–30.
82. Duong T, Judd A, Collins I, Doerholt K, Lyall H, Foster C. Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland. *Aids*. 2014;28:2395–405.
83. Anggriani Y, Rianti A, Pontoan J, Juwita Y. Analisis efektivitas terapi antiretroviral pada pasien HIV/AIDS rawat jalan di RSUP Fatmawati Jakarta tahun 2016. *J Ilm Ibnu Sina*. 2019;4:9–18.
84. Melkamu MW, Gebeyehu MT, Afenigus AD, Hibstie YT, Temesgen B, Petrucka P, et al. Incidence of common opportunistic infections among HIV-

- infected children on ART at Debre Markos referral hospital, Northwest Ethiopia: a retrospective cohort study. *BMC infectious diseases*. 2020;20(50):1–12.
85. Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, Farley J, et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the perinatal AIDS collaborative transmission study, 1986-2004. *Pediatrics*. 2007;120(1):100–9.
 86. Marais B, Rabie H, Schaaf S, Cotton M. Common opportunistic infections in HIV infected infants and children Part 1—respiratory infections. *S Afr Fam Pract*. 2006 Nov 1;48(10):52–6.
 87. Cohen S, ter Stege JA, Weijsenfeld AM, van der Plas A, Kuijpers TW, Reiss P, et al. Health-related quality of life in perinatally HIV-infected children in the Netherlands. *AIDS Care*. 2015 Oct 3;27(10):1279–88.
 88. Chawla KS, Rosenberg NE, Stanley C, Matoga M, Maluwa A, Kanyama C, et al. HIV and early hospital readmission : evaluation of a tertiary medical facility in Lilongwe , Malawi. *BMC Health Services Research*. 2018;18:1–9.
 89. Ford N, Vitoria M, Penazzato M, Doherty M, Shubber Z, Meintjes G, et al. Causes of hospital admission among people living with HIV worldwide: A systematic review and meta-analysis. *The Lancet HIV*. 2015;2(10):1–7.
 90. Muhaimin T. Kualitas hidup anak remaja pada keluarga dengan HIV/AIDS di Indonesia. *Jurnal Kesehatan Masyarakat Nasional*. 2010;5(3):131–8.
 91. Ministry of Health and Social Welfare. National guidelines for the management of HIV and AIDS. Fifth edit. Tanzania: National AIDS Control Programme (NCAP); 2015. 1–290.
 92. Meidani M, Rezaei F, Maracy MR, Avijgan M. Prevalence, severity, and related factors of anemia in HIV/AIDS patients. *Journal of Research in Medical Sciences*. 2012;49(367):1–6.
 93. Panel of Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection T. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection Recognizing and Managing Antiretroviral Treatment Failure (.
 94. Mehta K, Heylen E, Shet A. Adherence to antiretoviral therapy among children living with HIV in South India. *AIDS Behav*. 2016;20(5):1076–83.
 95. Williams PL, Jesson J. Growth and pubertal development in HIV-infected adolescents. *Curr Opin HIV AIDS*. 2018 May 1;13(3):179–86.
 96. Waterlow J. Classification and definition of protein-calorie malnutrition. *Br Med J*. 1972;3(5826):566–9.



97. Centers for Disease Control and Prevention. *Epidemiology and Prevention of Vaccine-Preventable Diseases*. 14th ed. Hall E, Woodi A, Hamborsky J, editors. Vol. 14th edition. Washington D.C.: Public Health Foundation; 2021.
98. Pengurus Pusat Ikatan Dokter Anak Indonesia. *Rekomendasi Ikatan Dokter Anak Indonesia Terkait Pemberian Vaksin COVID-19 pada Anak dan Remaja*. 2021.
99. Unit Kerja Koordinasi Endokrinologi IDAI. *Panduan Praktik Klinis Ikatan Dokter Anak Indonesia: Perawakan Pendek pada Anak dan Remaja di Indonesia*. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia; 2017.
100. Ndagije F, Baribwira C, Coulter JBS. Micronutrients and T-cell subsets: A comparison between HIV-infected and uninfected, severely malnourished Rwandan children. *Ann Trop Paediatr*. 2007 Dec;27(4):269–75.
101. Grinspoon S, Mulligan K. Weight Loss and Wasting in Patients Infected with Human Immunodeficiency Virus. *Clin Infect Dis*. 2003;36(2):S69–78.
102. Poda GG, Hsu CY, Chao JCJ. Malnutrition is associated with HIV infection in children less than 5 years in Bobo-Dioulasso City, Burkina Faso: a case-control study. *Medicine*. 2017 May 1;96(21).
103. Adinani H, Campbell L, El-Mallawany NK, Slone J, Mehta P, Bacha J. Use of paclitaxel to successfully treat children, adolescents, and young adults with Kaposi sarcoma in southwestern Tanzania. *Children*. 2021 Apr 1;8(275).
104. Shet A, Arumugam K, Rajagopalan N, Dinakar C, Krishnamurthy S, Mehta S, et al. The prevalence and etiology of anemia among HIV-infected children in India. *Eur J Pediatr*. 2012 Mar;171(3):531–40.
105. UKK Endokrinologi Anak dan Remaja IDAI. *Buku Ajar Endokrinologi Anak*. Cetakan Pertama. Batubara J, Tridjaja B, Pulungan A, editors. Jakarta: Ikatan Dokter Anak Indonesia; 2010.
106. Piwoz E. Nutrition and HIV/AIDS: Evidence, Gaps, and Priority Actions. 2014;1–6.
107. Banerjee T, Pensi T, Banerjee D, Grover G. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India. *Ann Trop Paediatr*. 2010;30(1):27–37.
108. Varni JW. *Scaling and Scoring of the Pediatric Quality of Life Inventory (PedsQL)*. 2017.
109. Adnyana IGANS, Gunardi H, Kurniati N. Quality of Life of Children With HIV Infection. | *Int J Clin Pediatr Child Health*. 2019;1(1).
110. Fajriyah YL, Demartoto A, Murti B. The Effect of Depression, Stigma, and Peer Support Group, on the Quality of Life of People Living with HIV/AIDS in Solo Plus Peer Support Group, Surakarta, Central Java. *J Health Promotion Behav*. 2018;03(01):27–36.



111. Balgis, Fortuna P, Hifli L. The Relationship Between HIV Incidence Rate, District/ Municipality Health Budget, Healthy House Rate, and Tuberculosis Prevalence in Indonesia. *J Epid Public Health*. 2016;01(03):164–74.
112. Majaliwa E, Mohn A, Chiarelli F. Growth and puberty in children with HIV infection. *J Endocrinol Invest*. 2009;32:85–90.
113. Krown SE, Moser CB, MacPhail P, Matining RM, Godfrey C, Caruso SR, et al. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. *The Lancet*. 2020 Apr 11;395(10231):1195–207.
114. Torres HA, Mulanovich V. Management of HIV infection in patients with cancer receiving chemotherapy. *Clin Infect Dis*. 2014 Jul 1;59(1):106–14.
115. Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. *AIDS*. 2002;16:531–6.
116. Haileamlak A, Hagos T, Abebe W, Abraham L, Asefa H, Teklu AM. Predictors of Hospitalization among Children on ART in Ethiopia: a Cohort study. *Ethiop J Health Sci*. 2017 Feb 1;27(1):53–62.
117. Nesheim SR, Balaji A, Hu X, Lampe M, Dominguez KL. Opportunistic Illnesses in Children With HIV Infection in the United States, 1997-2016. *Pediatr Infect Dis J*. 2021 Jul 1;40(7):645–8.
118. Moreira-Silva SF, Zandonade E, Miranda AE. Mortality in children and adolescents vertically infected by HIV receiving care at a referral hospital in Vitoria, Brazil. *BMC Infect Dis*. 2015 Mar 25;15(1).
119. Collins IJ, Jourdain G, Hansudewechakul R, Kanjanavanit S, Hongsiriwon S, Ngampiyasakul C, et al. Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: A 5-year observational cohort study. *Clin Infect Dis*. 2010 Dec 15;51(12):1449–57.
120. World Health Organization. Consolidated Guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Second edition. Geneva: World Health Organization; 2016.
121. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. *AIDS*. 1999;13:943–50.
122. Semba RD, Gray GE. Pathogenesis of Anemia During Human Immunodeficiency Virus Infection. *J Investig Med*. 2001;49(3).
123. Indian Council of Medical Research (ICMR). Iron absorption and its implications on strategies to control iron deficiency anaemia. *ICMR Bull*. 2000;30(2).



124. Kupka R, Msamanga GI, Mugusi F, Petraro P, Hunter DJ, Fawzi WW. Iron Status Is an Important Cause of Anemia in HIV-Infected Tanzanian Women but Is Not Related to Accelerated HIV Disease Progression. *J Nutr.* 2007;137:2317–23.
125. van Lettow M, van der Meer JWM, West CE, van Crevel R, Semba RD. Interleukin-6 and human immunodeficiency virus load, but not plasma leptin concentration, predict anorexia and wasting in adults with pulmonary tuberculosis in Malawi. *J Clin Endocr Metab.* 2005 Aug;90(8):4771–6.
126. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. *Blood.* 2003;101(7).
127. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. *J Clin Invest.* 2004 May;113(9):1271–6.
128. Chalasani N, Wilcox CM. Gastrointestinal Hemorrhage in Patients with AIDS. *AIDS Patient Care STDs.* 1999;13(6).
129. Yildiz T, Aydin DB, Ilce Z, Yucak A, Karaaslan E. External hemorrhoidal disease in child and teenage: Clinical presentations and risk factors. *Pak J Med Sci.* 2019 May 1;35(3):696–700.
130. Johanson JF. Nonsurgical Treatment of Hemorrhoids. *Journal of Gastrointestinal Surgery.* 2002;6(3).
131. Lohsiriwat V. Hemorrhoids: From basic pathophysiology to clinical management Varut Lohsiriwat. *World J Gastroenterol.* 2012;18(17):2009–17.
132. Wiersma H, Escher JC, Dilger K, Trenk D, Benninga MA, van Boxtel CJ, et al. Pharmacokinetics of Mesalazine Pellets in Children With Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2004;10(5).
133. Shet A, Bhavani PK, Kumarasamy N, Arumugam K, Poongulali S, Elumalai S, et al. Anemia, diet and therapeutic iron among children living with HIV: A prospective cohort study. *BMC Pediatr.* 2015 Oct 19;15(1).